Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

Summary Background In men with localised prostate cancer, conformal radiotherapy (CFRT) could deliver higher doses of radiation than does standard-dose conventional radical external-beam radiotherapy, and could improve long-term efficacy, potentially at the cost of increased toxicity. We aimed to pr...

Full description

Saved in:
Bibliographic Details
Published in:The lancet oncology 2007-06, Vol.8 (6), p.475-487
Main Authors: Dearnaley, David P, Dr, Sydes, Matthew R, CStat, Graham, John D, FRCR, Aird, Edwin G, PhD, Bottomley, David, FRCR, Cowan, Richard A, FRCR, Huddart, Robert A, FRCR, Jose, Chakiath C, FRACR, Matthews, John HL, FRACR, Millar, Jeremy, FRACR, Moore, A Rollo, MSc, Morgan, Rachel C, MSc, Russell, J Martin, FRCR, Scrase, Christopher D, FRCR, Stephens, Richard J, Syndikus, Isabel, FRCR, Parmar, Mahesh KB, DPhil
Format: Article
Language:English
Subjects:
Aged
Androgen Antagonists - therapeutic use
Androgens
Cancer therapies
Disease control
Disease-Free Survival
Hematology, Oncology and Palliative Medicine
Humans
Male
Metastasis
Middle Aged
Neoadjuvant Therapy
Prostate cancer
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - radiotherapy
Questionnaires
Radiation therapy
Radiotherapy Dosage
Radiotherapy, Conformal
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background In men with localised prostate cancer, conformal radiotherapy (CFRT) could deliver higher doses of radiation than does standard-dose conventional radical external-beam radiotherapy, and could improve long-term efficacy, potentially at the cost of increased toxicity. We aimed to present the first analyses of effectiveness from the MRC RT01 randomised controlled trial. Methods The MRC RT01 trial included 843 men with localised prostate cancer who were randomly assigned to standard-dose CFRT or escalated-dose CFRT, both administered with neoadjuvant androgen suppression. Primary endpoints were biochemical-progression-free survival (bPFS), freedom from local progression, metastases-free survival, overall survival, and late toxicity scores. The toxicity scores were measured with questionnaires for physicians and patients that included the Radiation Therapy Oncology Group (RTOG), the Late Effects on Normal Tissue: Subjective/Objective/Management (LENT/SOM) scales, and the University of California, Los Angeles Prostate Cancer Index (UCLA PCI) scales. Analysis was done by intention to treat. This trial is registered at the Current Controlled Trials website http://www.controlled-trials.com/ISRCTN47772397. Findings Between January, 1998, and December, 2002, 843 men were randomly assigned to escalated-dose CFRT (n=422) or standard-dose CFRT (n=421). In the escalated group, the hazard ratio (HR) for bPFS was 0·67 (95% CI 0·53–0·85, p=0·0007). We noted 71% bPFS (108 cumulative events) and 60% bPFS (149 cumulative events) by 5 years in the escalated and standard groups, respectively. HR for clinical progression-free survival was 0·69 (0·47–1·02; p=0·064); local control was 0·65 (0·36–1·18; p=0·16); freedom from salvage androgen suppression was 0·78 (0·57–1·07; p=0·12); and metastases-free survival was 0·74 (0·47–1·18; p=0·21). HR for late bowel toxicity in the escalated group was 1·47 (1·12–1·92) according to the RTOG (grade ≥2) scale; 1·44 (1·16–1·80) according to the LENT/SOM (grade ≥2) scales; and 1·28 (1·03–1·60) according to the UCLA PCI (score ≥30) scale. 33% of the escalated and 24% of the standard group reported late bowel toxicity within 5 years of starting treatment. HR for late bladder toxicity according to the RTOG (grade ≥2) scale was 1·36 (0·90–2·06), but this finding was not supported by the LENT/SOM (grade ≥2) scales (HR 1·07 [0·90–1·29]), nor the UCLA PCI (score ≥30) scale (HR 1·05 [0·81–1·36]). Interpretation Escalated-dose CFRT with
ISSN:1470-2045
1474-5488
DOI:10.1016/S1470-2045(07)70143-2